Fluorescent dye encapsulated ZnO particles with cell-specific toxicity for potential use in biomedical applications

Fluorescein isothiocyanate (FITC)-encapsulated SiO 2 core-shell particles with a nanoscale ZnO finishing layer have been synthesized for the first time as multifunctional “smart” nanostructures. Detailed characterization studies confirmed the formation of an outer ZnO layer on the SiO 2 –FITC core....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of materials science. Materials in medicine 2009-01, Vol.20 (1), p.11-22
Hauptverfasser: Wang, Hua, Wingett, Denise, Engelhard, Mark H., Feris, Kevin, Reddy, K. M., Turner, Paul, Layne, Janet, Hanley, Cory, Bell, Jason, Tenne, Dmitri, Wang, Chongmin, Punnoose, Alex
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Fluorescein isothiocyanate (FITC)-encapsulated SiO 2 core-shell particles with a nanoscale ZnO finishing layer have been synthesized for the first time as multifunctional “smart” nanostructures. Detailed characterization studies confirmed the formation of an outer ZnO layer on the SiO 2 –FITC core. These ~200 nm sized particles showed promise toward cell imaging and cellular uptake studies using the bacterium Escherichia coli and Jurkat cancer cells, respectively. The FITC encapsulated ZnO particles demonstrated excellent selectivity in preferentially killing Jurkat cancer cells with minimal toxicity to normal primary immune cells (18% and 75% viability remaining, respectively, after exposure to 60 μg/ml) and inhibited the growth of both gram-positive and gram-negative bacteria at concentrations ≥250–500 μg/ml (for Staphylococcus aureus and Escherichia coli , respectively). These results indicate that the novel FITC encapsulated multifunctional particles with nanoscale ZnO surface layer can be used as smart nanostructures for particle tracking, cell imaging, antibacterial treatments and cancer therapy.
ISSN:0957-4530
1573-4838
DOI:10.1007/s10856-008-3541-z